Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia (NCT01737697), a randomized phase 3 study. The primary outcome is Exponential Rate of Change in Serum Potassium (S-K) Levels During the Initial 48 Hours of Study Drug Treatment..

2. Clinical Question

The study addressed two related questions. The acute phase examined change in serum potassium among subjects with levels between 5.0 - 6.5 mmol/l. The subacute phase examined whether once-daily treatment maintained normokalemic levels, defined in the study summary as 3.5 - 4.9 mmol/l, among subjects completing the acute phase. These questions concern different treatment periods and different aspects of potassium control: an early change and subsequent maintenance.

The registry lists hyperkalemia as the condition and reports enrollment of 754. The record does not establish that every enrolled participant contributed data to each phase or to each endpoint. It also does not report the number of participants analyzed for the primary endpoint. Consequently, the clinical question is clear from the study objectives, but the size and precision of any treatment effect cannot be assessed from the available outcome information.

3. Trial Design

This was a phase 3, randomized, parallel-group, quadruple-masked study comparing zirconium silicate with placebo. It is described as prospective and multicenter in its official title. The record lists an enrollment of 754 and a completed status. The study started on 2012-11-30, and primary completion was 2013-10-31. The registry record does not describe the sites or explain which groups of people were included in quadruple masking.

The trial had two phases. In the acute phase, participants were assigned to one of four oral zirconium silicate doses or placebo. Active treatment was given three times daily with meals for 48 hours. The placebo was described as silicified microcrystalline cellulose and was administered to mimic the experimental dosing. The primary endpoint concerns the initial 48 hours of study-drug treatment.

The subacute phase is described as randomized withdrawal. It involved participants completing the acute phase and examined maintenance of normokalemic levels. Active doses were given once daily before the morning meal for 12 days, with matched placebo groups. The registry lists placebo-matched groups for several subacute doses, as well as subacute treatment groups following acute-phase placebo. These phase-specific assignments make it important to distinguish acute-phase comparisons from subacute-phase comparisons rather than treating them as one continuous contrast.

The record names the intervention as zirconium silicate and also uses the abbreviation ZS. It does not report the randomization sequence method, allocation concealment procedure, detailed masking procedures, or the number of participants assigned to each treatment group. Further details of the protocol and the statistical analysis plan are not reported in the registry record. The posted design therefore identifies the broad structure and schedules, but not all operational details needed to reproduce the trial methods.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: In the acute phase, 754 subjects were randomized; 753 were treated. Subjects who completed the AP and had i-STAT K+ values within normal range in a.m. of Study Day 3 could enter the Subacute Phase. 543 subjects entered the subacute phase.

Only the first 6 of 15 groups are shown.

Acute Phase-Initial 48 Hours

Reasons for not completing this period:

Subacute Phase

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: ITT Population

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: One subject in ZS 5g group was randomized but was not treated and is excluded from baseline characatertics.

6. Primary Endpoint

The registry lists the primary outcome as Exponential Rate of Change in Serum Potassium (S-K) Levels During the Initial 48 Hours of Study Drug Treatment., measured over Through 48 hours acute phase.

The primary endpoint is the exponential rate of change in serum potassium (S-K) levels during the initial 48 hours of study-drug treatment. Its unit is log(mmol/L)/hour, and the record identifies the measure as a mean with standard error. The specified timeframe is through 48 hours in the acute phase, and the stated analysis population is the ITT Population.

The endpoint represents change over time rather than a single potassium measurement at one visit. In general, a rate-of-change measure can describe the direction and pace of a biomarker's movement across a defined period. The logarithmic scale and exponential-rate wording indicate that the outcome is expressed as a rate on a transformed scale; the registry does not give further computational details about how the rate was estimated.

This type of endpoint is used to characterize the early response pattern during a short treatment period. It aligns with the acute-phase question of whether serum potassium changes over the first 48 hours. It is distinct from the secondary outcomes that refer to normalization, mean change, and mean percent change at time points, and it does not by itself describe whether a participant reached or maintained a particular potassium range.

The registry record does not report a primary endpoint estimate, standard error, confidence interval, or treatment-comparison test result. Thus, the endpoint's intended meaning can be described, but its observed magnitude, precision, and direction across treatment groups cannot be evaluated from the record information available for this analysis.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary measure is continuous: it is the exponential rate of change in serum potassium over the first 48 hours. The record labels the summary as a mean and gives standard error as the dispersion measure. A mean describes the center of a distribution of measured outcomes, while a standard error describes the estimated uncertainty in that mean under the statistical method used. The standard error is not the same as the spread of individual participants' measurements.

What does a rate-of-change endpoint describe?

In general, a rate-of-change endpoint uses measurements over time to summarize a trajectory rather than relying on one measurement alone. A rate can capture how quickly a measure changes during the defined observation period. In this study, the registered scale is log(mmol/L)/hour and the timeframe is through 48 hours in the acute phase. The registry does not specify the exact estimation model, the scheduled measurement times, or how incomplete measurement sequences were handled. Those details are not reported in the registry record.

The primary endpoint is identified for the ITT Population. In general, an intention-to-treat analysis aims to retain participants in the groups to which they were assigned, but the registry does not define its implementation for this study. It does not report whether participants with missing measurements were included through a particular method, how protocol deviations were treated, or how the analysis population was derived. The label alone does not resolve those methodological details.

How should uncertainty be understood?

In general, a confidence interval gives a range of estimates compatible with the observed data and the assumptions of the analysis. A narrow interval indicates greater precision than a wide interval, while neither width nor location can be assessed without the numerical interval. A standard error can contribute to estimating uncertainty, but no primary endpoint estimate or standard error value is reported in the registry record. Therefore, the precision of the primary comparison cannot be described.

A statistical test, when reported, evaluates the data relative to a specified null hypothesis and analysis procedure. The study summary states a null hypothesis of no difference between zirconium silicate and placebo for the acute phase. The record does not report a test statistic, p-value, degrees of freedom, or treatment contrast for the primary endpoint. It also does not report whether the analysis used a model that adjusted for baseline values, repeated measurements, site, or other covariates. These procedures should not be inferred from the endpoint name or trial design.

What does the planning illustration mean?

The record includes assumptions for a planning illustration based on the observed effect: a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is expressed as a stated fraction of the observed effect. Such calculations are prospective planning illustrations, not estimates of the trial's observed power. They do not establish the trial's original sample-size justification, and the registry does not report that justification. The record's stated assumptions do not include a numerical sample-size result in the information available for this analysis.

In general, a planning calculation asks how many participants may be needed under chosen assumptions about effect size, variability, significance level, and allocation. Its answer depends on those assumptions. When the effect used is based on an observed result, the calculation is still a planning illustration and should not be presented as the trial's actual power after completion. The registry record does not report the original assumptions used to design the study or whether the planned enrollment was based on the primary outcome.

Why can outcome variability matter?

General statistical methods may need to account for over-dispersion when observed variability exceeds what a model assumes. Greater variability can make estimates less precise and can affect standard errors and tests. The registry does not report a dispersion assessment or indicate whether over-dispersion was examined for this endpoint. No conclusion about it can be drawn for this study. Similarly, the record does not describe distributional checks, model diagnostics, transformations beyond the endpoint's log-scale wording, or sensitivity analyses.

The study has multiple outcomes, including normalization, change at time points, and maintenance measures. General statistical practice distinguishes a prespecified primary outcome from secondary or exploratory outcomes, and considers how multiple comparisons may affect the interpretation of statistical evidence. The registry identifies one primary endpoint but does not report the full analysis plan or multiplicity procedure. As a result, the handling of multiple doses, time points, phases, and outcomes cannot be reconstructed from the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry identifies the exponential rate of change in serum potassium during the initial 48 hours as the primary endpoint and lists additional outcomes relating to normalization, changes at multiple time points, and maintenance during the subacute phase. These outcomes involve more than one treatment dose and more than one period of assessment. The record does not describe a hierarchy of hypotheses, a family-wise error procedure, or another multiplicity adjustment. The approach to multiplicity is not reported in the registry record.

In general, multiple statistical comparisons can increase the chance of finding an apparently unusual result by chance if each is interpreted independently. Prespecifying a primary comparison and any adjustment strategy helps clarify how evidence should be interpreted. The registry's identification of a primary endpoint does not itself establish how comparisons among the several doses, time points, and phases were handled. No unreported correction or testing hierarchy should be assumed.

Missing-data methods are also not described. The registry does not report the amount or pattern of missing primary outcome measurements, how participants who discontinued were handled, whether imputation was used, or whether sensitivity analyses assessed the effect of missingness. The analysis population is labeled ITT, but its definition and the number analyzed are not reported. These gaps matter because the handling of unavailable measurements can affect both estimates and their uncertainty.

Enrollment was 754, but the record does not provide endpoint-specific analysis counts. It also does not state whether the primary analysis included every randomized participant or whether exclusions were made for any reason. As a result, the completeness of outcome data and the relationship between enrollment, randomization, and analysis cannot be assessed from the registry information. Details of the statistical analysis plan, including any interim analyses, are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: malaise (2.4%), pneumonia (2.2%), urinary retention (2.2%), chest pain (2.0%), blood potassium increased (2.0%).

The safety record separates acute-phase and subacute-phase treatment groups. For each group, it lists the number at risk and the number affected by serious adverse events, along with a separate count for other adverse events. For example, the acute-phase placebo group lists 158 at risk and 1 with a serious adverse event; the acute-phase zirconium silicate groups list 154, 141, 157, and 143 at risk, with 0 serious adverse events reported in each group. These are group-specific counts and should be read in the context of their listed denominators.

In the subacute phase, the groups have different numbers at risk and serious-event counts. For instance, the placebo matched to 1.25g lists 41 at risk and 1 affected, while the 1.25 g once-daily zirconium silicate group lists 49 at risk and 2 affected. The remaining group counts are likewise listed by treatment group and phase. Because the subacute phase is a randomized withdrawal among acute-phase completers, its groups should not be conflated with the broader acute-phase groups.

The registry also lists serious adverse-event terms with percentages, including malaise, pneumonia, urinary retention, chest pain, blood potassium increased, and dyspnoea. It does not assign those listed term percentages to treatment groups in the information. Death counts are not reported in the registry record; null entries should not be interpreted as evidence of no deaths. These data are descriptive and do not by themselves establish a causal difference between treatments.

12. What the Result Does, and Does Not, Mean

The registry record describes a randomized, masked, placebo-controlled study with an acute phase and a subacute randomized-withdrawal phase. It establishes that the study was designed to assess early serum potassium change and later maintenance of normokalemic levels. It also specifies the primary endpoint and identifies the ITT Population as the primary analysis population. Those details clarify the intended scientific questions.

What the record does not show is the numerical primary endpoint result. There is no reported estimate of the exponential rate of change, no standard error value, and no confidence interval or treatment comparison result. Therefore, the magnitude, direction, and precision of the primary treatment contrast cannot be determined from the registry information. The study's stated hypothesis is not a result, and the design alone does not establish whether the data favored either group.

The registry lists several secondary outcomes but does not give their numerical results in the record information. It is therefore not possible to describe the frequency of normalization, the time spent normokalemic, or changes from baseline by treatment group. Similarly, the listed safety counts can be described, but they do not provide a complete basis for comparing risks. The record does not report deaths, and that should not be taken to mean that no deaths occurred.

In general, interpretation of a trial requires the observed effect, its uncertainty, the analysis population, and information about missing data and multiplicity. Here, several of those components are not reported in the registry record. The enrollment of 754 should not be treated as the number analyzed for every outcome, and the planning illustration should not be treated as observed power. The appropriate statistical reading is consequently limited: the design and objectives are documented, some safety counts are available, but the primary efficacy estimate and many details needed to evaluate it are absent.

13. Why This Trial Matters Statistically

This trial illustrates why a detailed design description and reported outcome estimates play different roles in statistical interpretation. The randomized, parallel-group, quadruple-masked structure describes how the study was organized, while the primary endpoint identifies what it intended to measure: the exponential rate of serum potassium change during the first 48 hours. Neither piece of information, by itself, tells a reader the size or precision of the treatment contrast.

The two-phase structure also makes the estimand important. The acute phase focused on early change across several doses and placebo. The subacute phase was a randomized withdrawal among participants completing the acute phase and focused on maintaining normokalemic levels. These are related but distinct questions, based on different treatment schedules and populations. Treating them as a single comparison would obscure the design's separate objectives.

The record also demonstrates the value of transparent analysis reporting. The primary population is named, but its definition and analyzed sample size are not reported. The record does not describe missing-data handling, the multiple-comparison strategy, or the primary analysis model. These details influence how estimates should be understood and whether results can be independently evaluated. Their absence limits assessment even where the clinical question and broad trial design are clear.

Finally, the registry includes planning assumptions and descriptive safety information, but neither replaces the primary outcome estimate. A planning illustration is not observed power, and event counts without full comparative context should not be turned into causal claims. Statistically, this study is a useful case for separating protocol intent, analysis methods, precision, and the results actually reported in a registry.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation for interpreting the trial is that numerical results for the primary endpoint are not reported in the registry record. The primary estimate, its standard error, a confidence interval, and a treatment-comparison test result are unavailable. The listed secondary outcomes also lack results in the record information, preventing assessment of the normalization and maintenance questions.

The registry gives an enrollment of 754 but does not report treatment-group enrollment or the number analyzed for the primary endpoint. Although the primary population is called ITT, its operational definition is not included. The record also does not describe missing outcome data, exclusions, discontinuations, or methods used to handle unavailable measurements. These gaps prevent assessment of analysis completeness and potential bias from missingness.

The method used to estimate the rate of change is not described in detail. The record does not specify the measurement schedule, model form, covariate adjustment, model diagnostics, or sensitivity analyses. It does not state whether multiple doses and time points were handled using a prespecified testing hierarchy or multiplicity adjustment. Sample-size justification and interim-analysis plans are not reported in the registry record.

Safety interpretation is limited as well. Serious adverse-event counts are listed by group, but deaths are not reported, and the record does not provide all details needed for a comparative safety analysis. The serious-event terms and percentages are not assigned to specific treatment groups in the information available. Taken together, these limitations mean the design and objectives can be described, but the balance of treatment effects, their precision, and the robustness of the analyses cannot be fully evaluated from the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia — NCT01737697.
• Registry record last updated 2018-10-12; status last verified 2018-09.
• Results first posted 2018-10-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01737697 is a completed phase 3 randomized, parallel-group, quadruple-masked study of zirconium silicate and placebo for hyperkalemia. Enrollment was 754. The study began on 2012-11-30, with primary completion on 2013-10-31.

The acute phase compared four zirconium silicate doses with placebo over 48 hours, with dosing three times daily with meals. Its primary endpoint was the exponential rate of change in serum potassium, measured in the ITT Population. The subacute randomized-withdrawal phase assessed once-daily treatment for 12 days among subjects completing the acute phase, with maintenance of normokalemic levels as a study question.

The registry record does not report the numerical primary endpoint estimate, its uncertainty, or a treatment-comparison result. It also does not report detailed methods for missing data, multiplicity, or the primary analysis model. Serious adverse-event counts are listed by treatment group; death counts are not reported in the registry record.